ADAM9 is altered in 0.02% of all cancers with breast invasive ductal carcinoma, esophageal adenocarcinoma, high grade ovarian serous adenocarcinoma, intrahepatic cholangiocarcinoma, and ovarian carcinosarcoma having the greatest prevalence of alterations .
The most common alterations in ADAM9 are ADAM9-FGFR1 Fusion (0.05%), ADAM9-FGFR2 Fusion (0.00%), and ADAM9-WHSC1L1 Fusion (0.02%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.